Abstract
The most common PET radioisotopes, both in the literature and in clinical practice, are the cyclotron produced 11C and 18F, giving rise to tracers with minimal chemical changes with respect to the original biological molecule. However, the short half-life of these two radioisotopes and the relatively complex chemistry of their incorporation into the molecules of interest limits the number of molecules that really can be labelled in a suitable length of time. 68Ga is a positron emitter, produced by a 68Ge/68Ga generator rending the production of its radiopharmaceuticals independent of an onsite cyclotron. This paper covers the main aspects of the Ga3+ coordination chemistry together with the state of art of its radiopharmacy.
Keywords: Bioconjugates, PET imaging, nuclear probes, 68Ge/68Ga generator, gallium-68, MSH, Peptides, Imaging, Antibodies
Current Radiopharmaceuticals
Title: Gallium-68: A New Trend in PET Radiopharmacy
Volume: 5 Issue: 2
Author(s): M. Isabel M. Prata
Affiliation:
Keywords: Bioconjugates, PET imaging, nuclear probes, 68Ge/68Ga generator, gallium-68, MSH, Peptides, Imaging, Antibodies
Abstract: The most common PET radioisotopes, both in the literature and in clinical practice, are the cyclotron produced 11C and 18F, giving rise to tracers with minimal chemical changes with respect to the original biological molecule. However, the short half-life of these two radioisotopes and the relatively complex chemistry of their incorporation into the molecules of interest limits the number of molecules that really can be labelled in a suitable length of time. 68Ga is a positron emitter, produced by a 68Ge/68Ga generator rending the production of its radiopharmaceuticals independent of an onsite cyclotron. This paper covers the main aspects of the Ga3+ coordination chemistry together with the state of art of its radiopharmacy.
Export Options
About this article
Cite this article as:
Isabel M. Prata M., Gallium-68: A New Trend in PET Radiopharmacy, Current Radiopharmaceuticals 2012; 5 (2) . https://dx.doi.org/10.2174/1874471011205020142
DOI https://dx.doi.org/10.2174/1874471011205020142 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiolabeled Compounds in the Development of Cytotoxic Agents
Current Pharmaceutical Design Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia
Current Pharmaceutical Design T11TS/SLFA-3 Differentially Regulate the Population of Microglia and Brain Infiltrating Lymphocytes to Reduce Glioma by Modulating Intrinsic Bcl-2 Expression rather than p53
Central Nervous System Agents in Medicinal Chemistry The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Current Pharmaceutical Design Editorial [Hot Topic: Angiogenesis Agents (Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Clearing the Brains Cobwebs: The Role of Autophagy in Neuroprotection
Current Neuropharmacology Adult Neural Stem Cell Therapy: Expansion In Vitro, Tracking In Vivo and Clinical Transplantation
Current Drug Targets Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Current Topics in Medicinal Chemistry RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry